654 related articles for article (PubMed ID: 32245900)
21. Cell-Proliferation Imaging for Monitoring Response to CDK4/6 Inhibition Combined with Endocrine-Therapy in Breast Cancer: Comparison of [
Elmi A; Makvandi M; Weng CC; Hou C; Clark AS; Mach RH; Mankoff DA
Clin Cancer Res; 2019 May; 25(10):3063-3073. PubMed ID: 30692100
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
23. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
[TBL] [Abstract][Full Text] [Related]
24. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
25. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
27. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
Jin X; Ge LP; Li DQ; Shao ZM; Di GH; Xu XE; Jiang YZ
Mol Cancer; 2020 May; 19(1):87. PubMed ID: 32393270
[TBL] [Abstract][Full Text] [Related]
28. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
Herrera-Abreu MT; Palafox M; Asghar U; Rivas MA; Cutts RJ; Garcia-Murillas I; Pearson A; Guzman M; Rodriguez O; Grueso J; Bellet M; Cortés J; Elliott R; Pancholi S; Baselga J; Dowsett M; Martin LA; Turner NC; Serra V
Cancer Res; 2016 Apr; 76(8):2301-13. PubMed ID: 27020857
[TBL] [Abstract][Full Text] [Related]
29. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
30. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
[TBL] [Abstract][Full Text] [Related]
31. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
Kettner NM; Vijayaraghavan S; Durak MG; Bui T; Kohansal M; Ha MJ; Liu B; Rao X; Wang J; Yi M; Carey JPW; Chen X; Eckols TK; Raghavendra AS; Ibrahim NK; Karuturi MS; Watowich SS; Sahin A; Tweardy DJ; Hunt KK; Tripathy D; Keyomarsi K
Clin Cancer Res; 2019 Jul; 25(13):3996-4013. PubMed ID: 30867218
[TBL] [Abstract][Full Text] [Related]
32. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
33. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
34. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial.
Arnedos M; Bayar MA; Cheaib B; Scott V; Bouakka I; Valent A; Adam J; Leroux-Kozal V; Marty V; Rapinat A; Mazouni C; Sarfati B; Bieche I; Balleyguier C; Gentien D; Delaloge S; Lacroix-Triki M; Michiels S; Andre F
Ann Oncol; 2018 Aug; 29(8):1755-1762. PubMed ID: 29893769
[TBL] [Abstract][Full Text] [Related]
35. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
[TBL] [Abstract][Full Text] [Related]
36. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M; Cureton N; Ros S; Cheraghchi-Bashi A; Urosevic J; D'Arcy S; Delpuech O; DuPont M; Fisher DI; Gangl ET; Lewis H; Trueman D; Wali N; Williamson SC; Moss J; Montaudon E; Derrien H; Marangoni E; Miragaia RJ; Gagrica S; Morentin-Gutierrez P; Moss TA; Maglennon G; Sutton D; Polanski R; Rosen A; Cairns J; Zhang P; Sánchez-Guixé M; Serra V; Critchlow SE; Scott JS; Lindemann JPO; Barry ST; Klinowska T; Morrow CJ; Carnevalli LS
Cancer Res; 2023 Dec; 83(23):3989-4004. PubMed ID: 37725704
[TBL] [Abstract][Full Text] [Related]
37. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Lee J; Im SA; Kim GM; Jung KH; Kang SY; Park IH; Kim JH; Ahn HK; Park YH
Cancer Res Treat; 2021 Jul; 53(3):695-702. PubMed ID: 33332933
[TBL] [Abstract][Full Text] [Related]
38. HSulf‑1 and palbociclib exert synergistic antitumor effects on RB‑positive triple‑negative breast cancer.
Chen F; Zhang Z; Yu Y; Liu Q; Pu F
Int J Oncol; 2020 Jul; 57(1):223-236. PubMed ID: 32377705
[TBL] [Abstract][Full Text] [Related]
39. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
40. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
